Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838270 | 0.82 | ALDH1A1 (0.42) | CYP19A1MTORADKNISCHALDH1A1 | |
| SCHEMBL2697752 | 0.81 | MTOR (0.42) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL6302051 | 0.79 | CYP19A1 (0.47) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL697087 | 0.79 | CYP19A1 (0.47) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL5240030 | 0.78 | CYP1A2 (0.38) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL11089506 | 0.77 | MTOR (0.45) | CYP19A1MTORADKNISCHTAAR1 | |
| Trityl Imidazole SCHEMBL1572623 | 0.77 | MTOR (0.45) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL5380824 | 0.74 | — | — | |
| SCHEMBL6090949 | 0.74 | CYP19A1 (0.64) | CYP19A1MTORADKNISCHTAAR1 | |
| SCHEMBL5676876 | 0.74 | CYP19A1 (0.46) | CYP19A1MTORADKNISCHTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | CYP19A1 3562/4885MTOR 2926/4885ADK 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.